Dato’ Dr Azmee Mohd Ghazi

Clinical Director, Heart Failure and Heart Transplant, Institut Jantung Negara (IJN), Malaysia

Dr David Sim

Cardiologist, Heart Failure Program Director, National Heart Center Singapore; Immediate past president of Heart Failure Society (Singapore)

Dr Joshua Chung

Cardiology Fellow, Pusat Jantung Sarawak, Malaysia

Home > Education & CME > Webinar > EMPORIUM – Full Throttle Against HF: From Detection to Protection

EMPORIUM – Full Throttle Against HF: From Detection to Protection

13 September 2024

KEY TAKEAWAYS

Role of NT-proBNP: a) as a risk predictor for diabetes mellitus; b) to exclude heart failure from dyspnoea, leg swelling or suspected heart failure cases; and c) for prognostication of established heart failure cases
SGLT2i has cardioprotective properties
If NT-proBNP is elevated in suspected heart failure cases, SGLT2i can be initiated before cardiology consult and echocardiography appointment

Key takeaways

References

Elecsys NT-proBNP v2.0 method sheet.
Roche. Media & Investor Release. Available at: https://assets.roche.com/imported/01_28042021_MR_Cardiac_Claim_Extensions_EN.pdf (accessed June 2024).
O’Rourke et al. 15(6) 461–468 Vascular Medicine 2010
Dzau et al Circulation. 2006;114:2850-2870.
Custodis et al. Journal of Cardiology 62 (2013) 183–187.
ADA Standards of Care. Diabetes Care. 2024;47(Suppl. 1):S179–S218

Updates from Leading Experts

STRONG-HF: Post-discharge Heart Failure Management and Implementation of GDMT Heart Failure Therapy

Prof Alexandre Mebazaa shares the key results and highlights from the STRONG-HF study that assessed the safety, tolerability of optimization of guideline directed medical therapy.

28 March 2023

Prof Alexandre Mebazaa

CANVAS study: NT-proBNP and CVD risk reduction

Can you give us a short description of the CANVAS program? The CANVAS program was a set of two trials, whose goal was to evaluate the role of an SGLT2...

1 July 2021

Dr James L Januzzi